Cencora, Inc. (NYSE:COR) Shares Sold by Catalyst Capital Advisors LLC

Catalyst Capital Advisors LLC lessened its stake in Cencora, Inc. (NYSE:COR) by 3.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,411 shares of the company’s stock after selling 1,164 shares during the period. Catalyst Capital Advisors LLC’s holdings in Cencora were worth $6,395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of COR. New Millennium Group LLC acquired a new position in Cencora in the second quarter valued at $26,000. TCTC Holdings LLC acquired a new position in Cencora in the first quarter valued at $29,000. TFO Wealth Partners LLC purchased a new stake in shares of Cencora in the first quarter valued at about $30,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the second quarter valued at about $30,000. Finally, Concord Wealth Partners purchased a new stake in shares of Cencora in the third quarter valued at about $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the subject of a number of research reports. Wells Fargo & Company upped their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. upped their target price on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Robert W. Baird cut their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Bank of America reissued a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Finally, Leerink Partners cut their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $259.44.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 15.80% of the stock is currently owned by company insiders.

Cencora Trading Down 0.2 %

Shares of COR opened at $233.89 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The firm’s 50-day moving average is $231.38 and its two-hundred day moving average is $230.57. Cencora, Inc. has a twelve month low of $191.11 and a twelve month high of $247.66. The firm has a market capitalization of $46.09 billion, a P/E ratio of 25.40, a PEG ratio of 1.45 and a beta of 0.44.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.